
Epizyme’s Q2 financial results have been derailed by the company’s decision to terminate further Phase 2 development of its lead …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

